CytomX Therapeutics Q2 2024 GAAP EPS $(0.08) Beats $(0.10) Estimate, Sales $25.115M Beat $19.995M Estimate
Author: Benzinga Newsdesk | August 08, 2024 05:39pm
CytomX Therapeutics (NASDAQ:
CTMX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. The company reported quarterly sales of $25.115 million which beat the analyst consensus estimate of $19.995 million by 25.61 percent. This is a 1.58 percent increase over sales of $24.724 million the same period last year.
Posted In: CTMX